Literature DB >> 3018285

Mammalian cell transformation by a murine retrovirus vector containing the avian erythroblastosis virus erbB gene.

A Gazit, J H Pierce, M H Kraus, P P Di Fiore, C Y Pennington, S A Aaronson.   

Abstract

A recombinant murine retrovirus vector containing the v-erbB gene of avian erythroblastosis virus was constructed to investigate v-erbB as a transforming gene for mammalian cells. A restriction fragment containing the v-erbB sequences from a molecular clone of avian erythroblastosis virus was inserted into a Moloney murine leukemia virus vector. The construct, designated MuLV/erbB, transformed NIH 3T3 cells at a high efficiency in the DNA transfection assay. Individual MuLV/erbB transfectants grew in soft agar and were tumorigenic. The transfectants contained v-erbB DNA sequences, expressed v-erbB-specific transcripts, and synthesized v-erbB-related glycoproteins. The majority of transfectants produced two major v-erbB gene products of 58 and 66 kilodaltons. However, some transfectants produced much smaller v-erbB-specific proteins. Tunicamycin experiments revealed that the size heterogeneity observed between different transfectants was not due to variations in glycoprotein processing, implying that, in some cases, alterations in the MuLV/erbB genome occurred during the transfection process. These findings indicate that expression of the complete v-erbB gene product is not required for transformation of NIH 3T3 cells. A transmissible murine v-erbB (M-erbB) virus was generated by infection of nonproducer transfectants with amphotrophic murine leukemia virus. Transmission of the rescued M-erbB virus was confirmed by DNA, RNA, and protein analyses. The introduction of a transforming v-erbB gene into mammalian cells by virus infection provides a means of analyzing the mechanism by which this epidermal growth factor receptor-related gene alters the growth and differentiation of cells from various lineages.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3018285      PMCID: PMC253897     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.

Authors:  R Mann; R C Mulligan; D Baltimore
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

2.  Identification and characterization of the avian erythroblastosis virus erbB gene product as a membrane glycoprotein.

Authors:  M J Hayman; G M Ramsay; K Savin; G Kitchener; T Graf; H Beug
Journal:  Cell       Date:  1983-02       Impact factor: 41.582

3.  The membrane glycoprotein encoded by the retroviral oncogene v-erb-B is structurally related to tyrosine-specific protein kinases.

Authors:  M L Privalsky; R Ralston; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

4.  The erbB gene of avian erythroblastosis virus is a member of the src gene family.

Authors:  T Yamamoto; T Nishida; N Miyajima; S Kawai; T Ooi; K Toyoshima
Journal:  Cell       Date:  1983-11       Impact factor: 41.582

Review 5.  Enhancer elements.

Authors:  G Khoury; P Gruss
Journal:  Cell       Date:  1983-06       Impact factor: 41.582

6.  Protein phosphorylation at tyrosine is induced by the v-erbB gene product in vivo and in vitro.

Authors:  T Gilmore; J E DeClue; G S Martin
Journal:  Cell       Date:  1985-03       Impact factor: 41.582

7.  Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences.

Authors:  J Downward; Y Yarden; E Mayes; G Scrace; N Totty; P Stockwell; A Ullrich; J Schlessinger; M D Waterfield
Journal:  Nature       Date:  1984 Feb 9-15       Impact factor: 49.962

8.  Sequencing the erbA gene of avian erythroblastosis virus reveals a new type of oncogene.

Authors:  B Debuire; C Henry; M Bernissa; G Biserte; J M Claverie; S Saule; P Martin; D Stehelin
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

9.  src- and fps-containing avian sarcoma viruses transform chicken erythroid cells.

Authors:  P Kahn; B Adkins; H Beug; T Graf
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

10.  Site-specific mutagenesis of avian erythroblastosis virus: erb-B is required for oncogenicity.

Authors:  L Sealy; M L Privalsky; G Moscovici; C Moscovici; J M Bishop
Journal:  Virology       Date:  1983-10-15       Impact factor: 3.616

View more
  6 in total

1.  The amino-terminal 14 amino acids of v-src can functionally replace the extracellular and transmembrane domains of v-erbB.

Authors:  M McMahon; R C Schatzman; J M Bishop
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

2.  Genetic determinants of neoplastic transformation by the retroviral oncogene v-erbB.

Authors:  A Wells; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

3.  The human transforming growth factor type alpha coding sequence is not a direct-acting oncogene when overexpressed in NIH 3T3 cells.

Authors:  E Finzi; T Fleming; O Segatto; C Y Pennington; T S Bringman; R Derynck; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

4.  Properties of a murine retroviral recombinant of avian acute leukemia virus E26: a murine fibroblast assay for v-ets function.

Authors:  C C Yuan; N Kan; K J Dunn; T S Papas; D G Blair
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

5.  Friend spleen focus-forming virus induces factor independence in an erythropoietin-dependent erythroleukemia cell line.

Authors:  S K Ruscetti; N J Janesch; A Chakraborti; S T Sawyer; W D Hankins
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

6.  Generation of fibrosarcomas in vivo by a retrovirus that expresses the normal B chain of platelet-derived growth factor and mimics the alternative splice pattern of the v-sis oncogene.

Authors:  M Pech; A Gazit; P Arnstein; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.